Home / Themes / MedTech '25: Diabetes Devices

MedTech '25: Diabetes Devices (open on stockthemes)

Last updated

Theme thesis · 5/5 sections · Tickers 5 with notes · 8 pending

Loading chart…
Loading…

Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).

Bull / Bear Details

Diabetes device makers are transitioning from core Type 1 cohorts into massive Type 2 and non-insulin markets, supported by expanding reimbursement, AID algorit

Thesis

Diabetes device makers are transitioning from core Type 1 cohorts into massive Type 2 and non-insulin markets, supported by expanding reimbursement, AID algorithm adoption, and pharmacy-channel access. While GLP-1 substitution risks and pricing compression persist, high-margin recurring consumables and underpenetrated wearable demand offer strong risk-adjusted upside.

Bull case

  • Expanded insurance coverage and clinical adoption of continuous glucose monitoring across intensive, basal, and non-insulin Type 2 populations drive recurring sensor demand far beyond established Type 1 cohorts, supported by favorable commercial payer policies and anticipated CMS coverage expansion.

  • Rapid technological progress in automated insulin delivery algorithms, tubeless patch form factors, and pharmacy-channel pay-as-you-go reimbursement lowers therapy friction and accelerates conversion from multiple daily injections into high-margin, sticky consumable streams.

  • Hardware and sensor innovation—including extended wear durations, multi-analyte detection (dual glucose-ketone monitoring), and fully closed-loop systems that eliminate meal-announcement burdens—broadens clinical utility, enhances user retention, and expands the addressable metabolic health footprint.

Bear case

  • Payer rebate demands, international price cuts, and emerging low-cost global manufacturers pressure sensor and pump gross margins, while extended sensor wear cycles risk muting annual consumable replacement unit growth if patient additions decelerate.

  • Rapid adoption and broader label expansions of GLP-1 and dual/triple incretin therapies threaten to delay or curb disease progression toward insulin dependence in Type 2 diabetes, capping the long-term addressable market for insulin delivery pumps and conventional injection consumables.

  • Connected health vulnerabilities—such as sensor calibration drift, delivery occlusions, algorithmic software defects, regulatory quality audit citations, and cybersecurity breaches—can trigger disruptive product recalls, commercial delays, and costly compliance remediation across device platforms.

Overview

Hiring Trend Watchpoints

High-performing diabetes device makers are actively pivoting commercial hiring away from saturated endocrinology clinics toward primary care sales forces and health system key account executives to capture the massive Type 2 diabetes opportunity. Look for dedicated postings in market access and pharmacy trade relations to manage pharmacy-benefit (PayGo) transitions and payer contracting. On the technical side, watch for sustained hiring in closed-loop control algorithms, embedded firmware, sensor electrochemistry, and AI predictive analytics. Accelerations in clinical trial project management confirm progress on fully closed-loop (unannounced meal) pipelines and multi-analyte sensors. Conversely, hiring freezes in primary care sales, reductions in field reimbursement coordinators, or rising turnover in regulatory quality compliance indicate channel friction, payer resistance, or execution delays.

Forum Watchlist

  • Reddit Community — r/diabetesHigh

    Patient sentiment on device usability, sensor failure rates, skin adhesion issues, and payer coverage shifts between Dexcom, Libre, and various pump systems.

  • Reddit Community — r/diabetes_t1High

    Feedback on automated insulin delivery algorithms (MiniMed 780G, Omnipod 5, Tandem Control-IQ, Beta Bionics iLet), loop performance, sensor accuracy during exercise, and unannounced meal handling.

  • Reddit Community — r/dexcomHigh

    Real-world wear experience for G7 15-day sensors, OTC Stelo adoption, direct-to-watch connectivity stability, and early chatter on next-generation G8 trials.

  • Reddit Community — r/OmnipodHigh

    Adoption dynamics of Omnipod 5, smartphone app operating system updates (iOS/Android compatibility), pod occlusion rates, and user sentiment transitioning from MDI to tubeless AID.

  • Online Patient Forum — TuDiabetes Community (tudiabetes.org)Medium

    Discussions on Medicare Advantage coverage rules, commercial pharmacy formulary exclusions, and real-world outcomes combining GLP-1 therapies with CGM and patch pumps.

Industry Publications

  • MedTech Dive (medtechdive.com) — Provides comprehensive daily coverage of FDA clearances, corporate quarterly earnings, payer reimbursement rulings, and competitive product launches across diabetes hardware.
  • diaTribe (diatribe.org) — Leading patient- and clinician-facing diabetes tech publication offering granular clinical trial reporting, device user feedback, and standard-of-care guidelines.
  • Diabetes Technology & Therapeutics (liebertpub.com/dia) — Peer-reviewed journal publishing pivotal clinical data on automated insulin delivery algorithms, continuous glucose sensor accuracy (MARD), and multi-analyte monitoring.
  • Medical Device and Diagnostics Industry (MD+DI) (mddionline.com) — Specialized coverage of medical device manufacturing, regulatory 510(k)/PMA trends, biosensor supply chain dynamics, and automated assembly scaling.
  • Fierce MedTech (fiercebiotech.com/medtech) — Delivers timely reporting on corporate strategic moves, MedTech spin-offs, M&A, venture funding in digital diabetes, and patent litigation.

Second Order Trends

Several second-order trends are reshaping diabetes device economics: First, automated insulin delivery is advancing from hybrid closed loops to fully closed-loop algorithms that completely eliminate meal announcements and carb counting (such as MiniMed Vivera and Insulet EVOLUTION), lowering cognitive barriers and accelerating adoption among primary-care managed Type 2 patients. Second, wearable continuous monitoring is expanding into multi-analyte biosensing, highlighted by dual glucose-ketone sensors (Abbott Libre Duo) designed to alert users to impending diabetic ketoacidosis. Third, real-world data demonstrates that GLP-1 medications act as powerful co-therapies rather than purely destructive substitutes, with patients combining GLP-1 receptor agonists and CGMs exhibiting superior glycemic outcomes and higher therapy adherence. Fourth, reimbursement channels are completing a structural migration from durable medical equipment (DME) channels with large upfront out-of-pocket pump costs toward recurring pharmacy-benefit pay-as-you-go models that accelerate new patient onboarding. Finally, over-the-counter metabolic biosensors (Dexcom Stelo, Abbott Lingo) are unlocking recurring cash-pay revenue among millions of individuals with prediabetes and lifestyle health goals.

Search Keywords Brand Product

  • Omnipod 5
  • Dexcom G7
  • FreeStyle Libre 3 Plus
  • MiniMed 780G
  • MiniMed Flex
  • MiniMed Fit
  • Tandem Mobi
  • iLet Bionic Pancreas
  • Control-IQ
  • Dexcom Stelo
  • Abbott Lingo
  • Libre Duo
  • Eversense 365
  • Simplera Sync
  • CareSens Air
  • iCan CGM
  • Equil patch pump
  • MiniMed Go
  • InPen
  • continuous glucose monitoring
  • automated insulin delivery
  • tubeless insulin pump
  • artificial pancreas
  • diabetes devices
  • blood glucose sensing
  • closed loop insulin delivery
  • smart insulin pens

Search Keywords Policy Regulatory

  • Medicare CGM coverage
  • Type 2 non-insulin coverage
  • CMS Physician Fee Schedule
  • ADA Standards of Care AID
  • FDA 510(k) automated insulin delivery
  • PBM pharmacy formulary access

Search Keywords Event Phrases

  • American Diabetes Association Scientific Sessions
  • Advanced Technologies & Treatments for Diabetes conference
  • EASD Annual Meeting
  • CMS CY 2027 Physician Fee Schedule final rule
  • Dexcom Investor Day

Google Trend Product Category Intent

• continuous glucose monitor • insulin pump • tubeless patch pump • automated insulin delivery • smart insulin pen • glucose biosensor

Google Trend Consumer Intent

• best continuous glucose monitor • how to get a CGM • patch pump for diabetes • over the counter CGM • Omnipod 5 vs Mobi • Libre vs Dexcom

Google Trend Macro Policy Terms

• Medicare CGM coverage type 2 • insurance cover continuous glucose monitor • ADA diabetes technology guidelines • GLP-1 and CGM coverage

Economic Data Watch

1. CMS — National Health Expenditure Accounts

Not in registry

Metric/field Total National Health Expenditures (NHE)

Cadence annual

Why it matters Overall healthcare spending indicates the market size and health for diagnostic and medical device services, directly impacting the addressable market for diabetes devices.

Signal to watch Increasing healthcare expenditures, especially in medical devices and home health, signal a growing market.

Confidence: high

2. FRED — Federal Funds Rate

Matchedfred · access=api · map_only

Metric/field FEDFUNDS

Cadence monthly

Why it matters Interest rates influence capital expenditure for healthcare providers, consumer spending on out-of-pocket medical costs, and the valuation of growth companies in MedTech.

Signal to watch Lowering or stable interest rates are generally bullish for MedTech, reducing borrowing costs and potentially increasing consumer discretionary healthcare spending.

Confidence: high

3. BLS — Consumer Price Index

Not in registryaccess=api

Metric/field CUUR0000SAM2

Cadence monthly

Why it matters Inflation, particularly in medical care services and medical care commodities, affects the cost of manufacturing and delivering diabetes devices, as well as the purchasing power of consumers.

Signal to watch Stable or declining inflation in medical care components is favorable, indicating manageable input costs and stable consumer affordability.

Confidence: high

4. Trading Economics — Canada Retail Sales

Not in registryaccess=scrape

Metric/field Canada Retail Sales Annual

Cadence monthly

Why it matters Retail sales in key international markets like Canada (where DexCom and Insulet have significant presence) can indicate consumer confidence and spending capacity, which indirectly affects adoption of medical devices sold through retail channels.

Signal to watch Consistent growth in retail sales suggests a healthy economic environment supporting international market expansion.

Confidence: high

5. Trading Economics — Ireland Industrial Production

Not in registryaccess=scrape

Metric/field Ireland Industrial Production

Cadence monthly

Why it matters Ireland is a key manufacturing hub for several MedTech companies, including DexCom. Industrial production data can signal supply chain health and manufacturing capacity trends.

Signal to watch Stable or increasing industrial production indicates robust manufacturing capabilities and fewer supply chain disruptions.

Confidence: high

Free Alt Data Watch

1. ClinicalTrials.gov — Clinical Trial Status

Not in registry

Metric/field Overall Status (e.g., 'Recruiting', 'Completed', 'Terminated')

Cadence daily

Why it matters Tracks the progress of new diabetes device technologies and therapies, indicating future product launches and market shifts. Early completion or positive status changes are bullish.

Signal to watch Increase in 'Recruiting' or 'Completed' trials for advanced AID systems, long-duration CGMs, or multi-analyte sensors.

Confidence: high

2. FDA — Medical Device 510(k) Clearances and PMA Approvals

Not in registry

Metric/field device_name, decision_date, product_code

Cadence daily

Why it matters FDA approvals and clearances are critical for launching new medical devices and diagnostics, directly impacting revenue growth and market penetration for theme companies.

Signal to watch Increase in 510(k) clearances or PMA approvals for continuous glucose monitors, insulin pumps, or automated insulin delivery systems.

Confidence: high

3. Google Trends — Search Interest

Not in registry

Metric/field continuous glucose monitor, wearable insulin pump, automated insulin delivery

Cadence daily

Why it matters Indicates general public awareness and interest in core theme technologies, signaling potential market adoption and patient demand.

Signal to watch Sustained increase in search interest for these terms suggests growing consumer awareness and potential market expansion.

Confidence: medium

4. Reddit Community — r/diabetes, r/diabetes_t1

Not in registry

Metric/field Post volume and sentiment related to Dexcom G7/Stelo, FreeStyle Libre, Omnipod 5, MiniMed Flex

Cadence daily

Why it matters Provides real-time patient sentiment, feedback on device wearability, failure rates, and discussions around payer coverage, offering early insights into product reception and market challenges.

Signal to watch Increasing positive sentiment and discussion volume around new product features or expanded coverage; conversely, negative sentiment or reports of issues could be bearish.

Confidence: medium

5. CMS — Medicare Physician Fee Schedule (PFS) Final Rule

Not in registry

Metric/field Reimbursement rates and policy changes for CPT codes related to RPM/RTM and CGM

Cadence annual (publication in Nov, effective Jan 1)

Why it matters CMS policy decisions on reimbursement for remote patient monitoring and continuous glucose monitoring directly impact the financial viability and adoption rates of these devices, especially for the Medicare population.

Signal to watch Favorable changes in reimbursement rates or expanded coverage for CGM and RPM services, particularly for Type 2 non-insulin patients.

Confidence: high

Paid Alt Data Watch

1. IQVIA — DeviceTrack

Not in registry

Metric/field Shipments of 'insulin pumps', 'CGM sensors' (by manufacturer, region)

Cadence monthly/quarterly

Why it matters Provides granular, real-world data on demand trends, market share, and competitive dynamics for core wearable diabetes devices.

Signal to watch Increasing shipment volumes for specific manufacturers' insulin pumps and CGM sensors, especially in new or expanding patient segments (e.g., Type 2 diabetes).

Confidence: high

2. Komodo Health — Healthcare Map

Not in registry

Metric/field CPT code utilization for CGM (e.g., 95250, 95251) and automated insulin delivery (e.g., specific pump codes) by patient type (Type 1, Type 2 insulin, Type 2 non-insulin)

Cadence monthly

Why it matters Measures real-world utilization growth for CGM and AID products under expanded insurance coverage, particularly for Medicare Advantage and Type 2 non-insulin patients.

Signal to watch Increasing claims volume for CGM and AID CPT codes, especially for Type 2 non-insulin patients, indicates successful market penetration and reimbursement.

Confidence: high

3. Similarweb — Web Traffic & App Usage

Matchedsimilarweb_website_traffic_engagement · access=file · map_only

Metric/field Website traffic (e.g., dexcom.com, omnipod.com) and mobile app downloads/engagement (e.g., Dexcom G7 app, Omnipod 5 app)

Cadence monthly

Why it matters Indicates consumer interest, brand engagement, and adoption of digital health platforms associated with diabetes devices.

Signal to watch Increasing web traffic and app engagement for leading diabetes device brands suggests growing user base and product stickiness.

Confidence: high

4. Definitive Healthcare — PhysicianView

Not in registry

Metric/field Prescribing patterns for endocrinologists and primary care physicians for CGM and insulin pumps

Cadence quarterly

Why it matters Tracks physician adoption and prescribing behavior, especially the expansion into primary care for Type 2 diabetes patients, which is a key growth driver for the theme.

Signal to watch Increase in the number of primary care physicians prescribing CGMs and insulin pumps, and higher prescription volumes from endocrinologists.

Confidence: high

5. Norstella — Payer Coverage & Reimbursement Reports

Matchednorstella_market_access_formulary · access=file · map_only

Metric/field Coverage policies and formulary access for continuous glucose monitors and automated insulin delivery systems by major commercial and government payers

Cadence irregular (event_driven by policy changes)

Why it matters Directly impacts market access and patient affordability for diabetes devices. Favorable policy changes can unlock significant market segments.

Signal to watch Expansion of insurance coverage for CGM and AID to broader patient populations (e.g., Type 2 non-insulin), and improved formulary access.

Confidence: high

Prediction Market Watch

1. Will the FDA approve a cure for Type 1 diabetes before 2033?

Kalshi · Confidence: high

Not in registryaccess=api

Market https://kalshi.com/markets/kxfdatype1diabetes

Why it matters A cure for Type 1 diabetes would fundamentally disrupt the market for companies heavily invested in diabetes management wearables, such as insulin pumps and continuous glucose monitors (CGMs). This directly impacts the core business model and long-term revenue streams of many theme constituents like DexCom (DXCM), Insulet (PODD), MiniMed (MMED), Tandem Diabetes Care (TNDM), Abbott (ABT), and Senseonics (SENS), as their products are designed to manage, not cure, the condition. A 'Yes' outcome would signal a significant long-term threat to the theme's constituents, while a 'No' outcome would reinforce the continued need for their devices.

Series key kalshi_fda_type1_diabetes_cure

Theme Plain English
MedTech '25: Diabetes Devices captures medical technology leaders commercializing wearable continuous glucose monitors, tubeless insulin patch pumps, automated insulin delivery systems, and advanced injection hardware. The theme tracks the structural shift from intermittent fingerstick testing and manual injections toward connected, automated closed-loop glycemic therapy. Growth is propelled by expanding reimbursement into insulin-treated and non-insulin Type 2 diabetes populations, automated algorithms that reduce patient cognitive burden, and multi-analyte continuous biosensing.
Key Metrics3 rows
MetricCadenceWhat It SignalsUpdate Source
Device prescriptions and shipments for wearable healthMonthlyTracks demand trends for wearable platforms across diabetes, cardiac, and neuro use.Google_Sheets
Remote monitoring reimbursement updates (CPT, HCPCS)QuarterlyCaptures policy progress for reimbursable wearable services across conditions.Google_Sheets
Medicare Advantage CGM and RPM claims volumeQuarterlyMeasures real-world utilization growth for DXCM, IRTC under expanded MA coverage.Google_Sheets
Upcoming Catalysts24 rows
CatalystEstimated TimingEstimated Date StartEstimated Date EndWhy It MattersTicker Or Theme SpecificSource TypesContributing TickersMention CountBase ScoreSource WeightSpecificity WeightMacro BridgeMacro Bridge MultiplierTheme ScoreDate AggregatedManual OverrideBridge Mention CountTheme Base ScoreTheme Importance ScoreSource TypeCatalyst SourceCatalyst IDTranscript Date
The Centers for Medicare & Medicaid Services (CMS) will publish the Calendar Year (CY) 2027 Physician Fee Schedule (PFS) final rule, which is expected to finalize significant proposed changes to remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) reimbursement policies.Final rule publication in November 2026; effective January 1, 2027.2026-11-012027-01-01This catalyst is critical as the proposed changes, including requiring RPM/RTM services to be furnished by direct employees and potentially consolidating CPT codes, could fundamentally alter the operational and financial models for companies providing remote monitoring solutions. It directly impacts the reimbursement landscape for wearable health devices.Themetheme_composerDXCM, IRTC, MYO30.0011.181.01.00.11292026-08-06False10.408548.1984Theme composer
Pharmaceutical companies (e.g., Novo Nordisk, Eli Lilly) will release Q3 and Q4 2026 earnings, providing updated prescription volume data and sales figures for GLP-1 medications, alongside anticipated FDA approvals and launches of new GLP-1 drugs like Novo Nordisk's CagriSema (late 2026) and Boehringer Ingelheim's survodutide (H1 2027).October-November 2026 (Q3 earnings), Q1 2027 (Q4 earnings and new drug launches).2026-10-012027-03-31The continued rapid adoption and expansion of GLP-1 therapies, particularly oral formulations and new market entrants, pose a significant substitution risk for continuous glucose monitoring (CGM) demand, directly impacting companies like Dexcom (DXCM).Themetheme_composerDXCM10.00081.180.92Regulatory/Policy1.350.11492026-08-06False10.00751.1014Theme composer
Potential Medicare coverage expansion for Libre Continuous Glucose Monitoring (CGM) for Type 2 non-insulin users in the US.in the fall2026-09-012026-11-30This could unlock a multibillion-dollar opportunity by accelerating commercial insurance coverage and reaching approximately 10 million Medicare beneficiaries, significantly boosting CGM sales.Tickerearnings_transcriptABT (ticker)ABT_79370e412026-07-16
FDA approval and US launch of Amulet 360 Left Atrial Appendage (LAA) device.by year-end 20262026-10-012026-12-31This device is designed to help reduce the risk of stroke in patients with AFib and is expected to reignite growth and capture market share in the LAA closure market.Tickerearnings_transcriptABT (ticker)ABT_30e24e432026-10-21
Broad U.S. launch of TactiFlex Duo catheter.starting in the fourth quarter2026-10-012026-12-31This catheter enables physicians to seamlessly switch between using RF and PFA energy during a procedure, which is expected to drive adoption and market share in electrophysiology.Tickerearnings_transcriptABT (ticker)ABT_7cc559f22026-10-21
Launch of Volt PFA catheter in Japan.sometime in Q42026-10-012026-12-31This launch is expected to turn Japan from a headwind to a tailwind for the electrophysiology business, contributing to international growth acceleration.Tickerearnings_transcriptABT (ticker)ABT_8bb43b0e2026-10-21
CMS to publish the CY 2027 Physician Fee Schedule final rule, finalizing changes to remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) reimbursement policies.Final rule publication in November 2026; effective January 1, 2027.2026-11-012027-01-01This rule could significantly alter the operational and financial models for companies providing remote monitoring solutions, directly impacting the reimbursement landscape for wearable health devices including Dexcom's offerings.Themeearnings_transcriptDXCM (ticker)DXCM_805547792026-07-30
CMS decision on coverage expansion for Type 2 non-insulin diabetes patients, following the submission of Connect trial data.before the end of this year2026-08-072026-12-31This decision has the potential to significantly expand the addressable market for Dexcom CGM in the US, impacting 25 million Type 2 non-insulin customers.Tickerearnings_transcriptDXCM (ticker)DXCM_e0606eaf2026-07-30
Dexcom expects to convert nearly 50% of its US customer base to the G7 15-day system.by year end2026-10-012026-12-31This conversion is translating into stronger customer satisfaction and is expected to contribute to improved gross margins.Tickerearnings_transcriptDXCM (ticker)DXCM_b887655c2026-07-30
European commercial launch of MiniMed Flex.November of this year2026-11-012026-11-30This launch follows CE Mark approval and is expected to drive strong growth in international markets by expanding reach into new patients and increasing competitive conversions.Tickerearnings_transcriptMMED (ticker)MMED_99ed28452026-09-01
Transition to direct commercial operations in additional key European markets, following the playbook from initial transitions.in the fourth quarter2026-10-012026-12-31Expected to improve price and margins (ASP premiums at least 30% higher) and deepen relationships, but also involves an anticipated $15 million headwind from distributor destocking and inventory buybacks for 2026.Tickerearnings_transcriptTNDM (ticker)TNDM_709c0ea72026-02-20
FDA clearance for Mobi Tubeless, enabling its commercial launch.second half of the year2026-07-012026-12-31Regulatory approval is necessary to launch this significant new product, which is Tandem's first patch pump and the world's first with extended wear technology, potentially impacting market share and revenue.Tickerearnings_transcriptTNDM (ticker)TNDM_82e30c2b2026-02-20
Commercial launch of Mobi Tubeless, a novel infusion site option for the Mobi pump that transforms it into a tubeless patch device.second half of the year2026-07-012026-12-31Introduces a new form factor and technology, potentially expanding Tandem's addressable market and competitive position against patch pump competitors, though not included in 2026 revenue guidance.Tickerearnings_transcriptTNDM (ticker)TNDM_a7005c102026-02-20
Initiation of a pivotal trial for Tandem's fully closed-loop automated insulin delivery algorithm.later this year2026-07-012026-12-31A crucial step towards developing a next-generation AID system, aiming for FDA filing in 2027, which is vital for maintaining Tandem's leadership in AID innovation.Tickerearnings_transcriptTNDM (ticker)TNDM_8eea9c452026-02-20
U.S. launch of Libre Duo, the world's first dual glucose ketone biowearable sensor.in December2026-12-012026-12-31This product allows people with diabetes to monitor ketones without traditional blood or urine tests, offering a new growth driver for the diabetes care business.Tickerearnings_transcriptABT (ticker)ABT_6009f9062026-10-21
The Centers for Medicare & Medicaid Services (CMS) is introducing a new "Software as a Medical Service" payment framework for algorithm-driven technologies in its Calendar Year (CY) 2027 payment rules, alongside ongoing updates and clarifications from the FDA regarding its AI framework and digital health guidance.January 1, 2027 (CMS framework effective date), ongoing throughout 2026-2027 (FDA guidance updates).2027-01-012027-12-31This catalyst provides a clearer regulatory and reimbursement pathway for AI-enhanced wearable platforms, potentially accelerating adoption and market entry for innovative diagnostic and monitoring solutions, benefiting companies integrating AI into their devices.Themetheme_composerIRTC, MYO, DXCM30.00111.180.92Regulatory/Policy1.350.16172026-08-06False10.408559.8624Theme composer
Significant U.S. payer formulary coverage for Libre goes into effect.January 12027-01-012027-01-01This expanded coverage is expected to be a nice growth driver for the diabetes business in the coming year.Tickerearnings_transcriptABT (ticker)ABT_c375ff522026-10-21
Regulatory filing for Insulet's fully closed-loop system for Type 2 diabetes.supporting a regulatory filing in 20272027-01-012027-12-31Successful regulatory filing is a prerequisite for commercial launch, enabling Insulet to access the vast and underpenetrated Type 2 diabetes market with a highly differentiated product, impacting future revenue and valuation.Tickerearnings_transcriptPODD (ticker)PODD_5dda514d2026-02-18
Commercial launch of Insulet's next-generation Omnipod 6 system.accelerate our innovation cycle as we prepare for launch in 20272027-01-012027-12-31This next-gen platform is designed to offer improved connectivity, flexibility, and personalized automation, crucial for maintaining competitive leadership and driving future revenue growth and investor sentiment.Tickerearnings_transcriptPODD (ticker)PODD_93a0b76a2026-02-18
The Heart Rhythm Society's annual meeting, Heart Rhythm 2027, will gather the global electrophysiology community to discuss groundbreaking science, clinical education, and innovations in cardiac pacing and electrophysiology.May 13-16, 2027.2027-05-132027-05-16This conference is crucial for companies in cardiac monitoring, as it showcases new research, product developments, and discussions on digital health and innovation relevant to wearable heart monitors and diagnostic devices.Themetheme_composerIRTC10.00011.181.05Conference/Council1.20.01332026-08-06False10.00090.1392Theme composer
Full U.S. launch of MiniMed Fit, a patch pump.by summer next year2027-06-012027-08-31Fit brings MiniMed's differentiated therapy platform to the fastest-growing segment of the insulin pump market, expanding reach into new patients and driving competitive conversions.Tickerearnings_transcriptMMED (ticker)MMED_216873912026-09-01
The 87th American Diabetes Association (ADA) Scientific Sessions will convene, bringing together professionals to share the latest developments in diabetes research, prevention, and care.June 18-21, 2027.2027-06-182027-06-21This major conference is a key platform for presenting new clinical data, technological advancements, and policy discussions related to diabetes management, directly impacting companies involved in continuous glucose monitoring and other diabetes-focused wearable health solutions.Themetheme_composerDXCM10.00081.181.05Regulatory/Policy, Conference/Council1.620.17052026-08-06False10.00751.5085Theme composer
Commercial launch of Insulet's fully closed-loop system for people with Type 2 diabetes.a commercial launch in 20282028-01-012028-12-31This system is designed to make AID accessible to virtually everyone with Type 2 diabetes, significantly expanding the addressable market and driving future growth, potentially solidifying Insulet's leadership in this segment.Tickerearnings_transcriptPODD (ticker)PODD_fdc63d7d2026-02-18
Insulet's new manufacturing facility in Costa Rica becomes operational.expected to be operational in 20292029-01-012029-12-31This investment in capacity and automation is critical for supporting long-term industry-leading growth and achieving continued margin expansion, impacting profitability and valuation.Tickerearnings_transcriptPODD (ticker)PODD_55d4bc0d2026-02-18
NotesTable

Earnings Summary

DateTypeCommentDetailSentimentTickers
2026-08-06Ticker AnalysisThe RxSight (RXST) transcript, focused on intraocular lenses for cataract surgery, has no direct relevance to the "MedTech Long '25: Wearable Health" theme. RXST's business model does not involve wearable or sensor-based platforms for chronic disease monitoring, mobility restoration, or cardiac/diabetes management, which are the core components of this theme.

Earnings Summary

NeutralRXST

News

3 stories tagged to this theme — Narrative Radar and editorial picks.

November 2026

October 2026

Loading correlation…

Constituents

  • ABTT3
    — Abbott Laboratories
  • — DexCom, Inc.
  • — MiniMed Group, Inc.
  • — Insulet Corp.
  • — Tandem Diabetes Care, Inc.
  • 099190.KOT3
    · no notes yet
  • 2235.HKT3
    · no notes yet
  • 294090.KQT3
    · no notes yet
  • 300298.SHET3
    · no notes yet
  • 6523.TT3
    · no notes yet
  • BBNXT3
    · no notes yet
  • EMBCT3
    · no notes yet
  • SENST3
    · no notes yet